Clinical trials: Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma

Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma

A Compassionate Use Program to Provide Access to Sodium Thiosulfate

• Available
• Age: 1 month to 18 years
• Expanded access

This is a CUP which is designed to provide treatment access of STS to pediatric patients for the protection from Cisplatin-Induced Hearing Loss in children who had standard-risk hepatoblastoma.

Trial name

NCT04132882

Testing

Sodium Thiosulfate (STS)

Where

Turkey (Türkiye)

Sponsor

TRPHARM